We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -7.67 | -4.58% | 159.6218 | 167.46 | 157.65 | 167.26 | 10,721,782 | 00:59:10 |
From Apr 2019 to Apr 2024
By Colin Kellaher
AbbVie Inc. (ABBV) on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of a shorter Maviret treatment duration in certain patients with chronic hepatitis C.
The North Chicago, Ill., biopharmaceutical company said the CHMP's positive opinion covers shortening the once-daily treatment duration to eight weeks from 12 in treatment-naive, compensated cirrhotic, chronic hepatitis C patients with genotype 3 infection.
AbbVie said the change, if approved by the European Commission, will make Maviret the only pan-genotypic eight-week treatment option for treatment-naive chronic hepatitis C patients, without cirrhosis or with compensated cirrhosis.
The EC, which generally follows the CHMP's recommendations, is expected make a decision this year, AbbVie said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 31, 2020 07:50 ET (12:50 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
